» Articles » PMID: 38191424

Single-cell Transcriptome Sequencing Reveals Aberrantly Activated Inter-tumor Cell Signaling Pathways in the Development of Clear Cell Renal Cell Carcinoma

Overview
Journal J Transl Med
Publisher Biomed Central
Date 2024 Jan 8
PMID 38191424
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Aberrant intracellular or intercellular signaling pathways are important mechanisms that contribute to the development and progression of cancer. However, the intercellular communication associated with the development of ccRCC is currently unknown. The purpose of this study was to examine the aberrant tumor cell-to-cell communication signals during the development of ccRCC.

Methods: We conducted an analysis on the scRNA-seq data of 6 ccRCC and 6 normal kidney tissues. This analysis included sub clustering, CNV analysis, single-cell trajectory analysis, cell-cell communication analysis, and transcription factor analysis. Moreover, we performed validation tests on clinical samples using multiplex immunofluorescence.

Results: This study identified eleven aberrantly activated intercellular signaling pathways in tumor clusters from ccRCC samples. Among these, two of the majors signaling molecules, MIF and SPP1, were mainly secreted by a subpopulation of cancer stem cells. This subpopulation demonstrated high expression levels of the cancer stem cell markers POU5F1 and CD44 (POU5F1CD44E.T), with the transcription factor POU5F1 regulating the expression of SPP1. Further research demonstrated that SPP1 binds to integrin receptors on the surface of target cells and promotes ccRCC development and progression by activating potential signaling mechanisms such as ILK and JAK/STAT.

Conclusion: Aberrantly activated tumor intercellular signaling pathways promote the development and progression of ccRCC. The cancer stem cell subpopulation (POU5F1CD44E.T) promotes malignant transformation and the development of a malignant phenotype by releasing aberrant signaling molecules and interacting with other tumor cells.

Citing Articles

Functional analysis of the effects of propofol on tamoxifen‑resistant breast cancer cells: Insights into transcriptional regulation.

Yin R, Gao J, Liu Y, Guo C Oncol Lett. 2025; 29(4):194.

PMID: 40041408 PMC: 11878209. DOI: 10.3892/ol.2025.14940.


New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunities.

Cesana B, Cochet C, Filhol O Int J Cancer. 2024; 156(3):475-487.

PMID: 39306698 PMC: 11622000. DOI: 10.1002/ijc.35181.


TUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma.

Li J, Chen M, Tong M, Cao Q Front Immunol. 2024; 15:1457691.

PMID: 39301023 PMC: 11410638. DOI: 10.3389/fimmu.2024.1457691.


Single-cell transcriptome sequencing reveals SPP1-CD44-mediated macrophage-tumor cell interactions drive chemoresistance in TNBC.

Liu F, Zhang J, Gu X, Guo Q, Guo W J Cell Mol Med. 2024; 28(13):e18525.

PMID: 38982317 PMC: 11233263. DOI: 10.1111/jcmm.18525.


Increased co-expression of 4-1BB with PD-1 on CD8+ tumor-infiltrating lymphocytes is associated with improved prognosis and immunotherapy response in cervical cancer.

Zhu X, Feng Y, Fan P, Dong D, Yuan J, Chang C Front Oncol. 2024; 14:1381381.

PMID: 38756662 PMC: 11096482. DOI: 10.3389/fonc.2024.1381381.

References
1.
Choueiri T, Pal S, McDermott D, Morrissey S, Ferguson K, Holland J . A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014; 25(8):1603-8. PMC: 6279111. DOI: 10.1093/annonc/mdu184. View

2.
Kindt N, Journe F, Laurent G, Saussez S . Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets. Oncol Lett. 2016; 12(4):2247-2253. PMC: 5038338. DOI: 10.3892/ol.2016.4929. View

3.
Tung C, Huang M, Liang C, Wu Y, Wu J, Hsu C . α-Catulin promotes cancer stemness by antagonizing WWP1-mediated KLF5 degradation in lung cancer. Theranostics. 2022; 12(3):1173-1186. PMC: 8771551. DOI: 10.7150/thno.63627. View

4.
Hao Y, Hao S, Andersen-Nissen E, Mauck 3rd W, Zheng S, Butler A . Integrated analysis of multimodal single-cell data. Cell. 2021; 184(13):3573-3587.e29. PMC: 8238499. DOI: 10.1016/j.cell.2021.04.048. View

5.
Hannigan G, Troussard A, Dedhar S . Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer. 2005; 5(1):51-63. DOI: 10.1038/nrc1524. View